Hoth Strengthens Global Patent Position for HT-KIT Cancer Program in China

Hoth Therapeutics has received approval from China's National Intellectual Property Administration for a patent covering its HT-KIT cancer program, expanding international protection for its targeted oncology platform. The patent covers technology designed to induce apoptosis in cancer cells by disrupting KIT-driven signaling pathways. Securing patent coverage in China strengthens Hoth's global IP position and supports future development and potential partnership opportunities for the HT-KIT program.